Get Madrigal Pharmaceuticals alerts:Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – B. Riley issued their Q3 2025 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report issued on Monday, September 29th. B. Riley analyst W. Wood expects that the biopharmaceutical company will post earnings per share of ($0.66) for the quarter. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at $0.83 EPS, FY2025 earnings at ($4.91) EPS, FY2026 earnings at $24.45 EPS, FY2027 earnings at $35.86 EPS and FY2028 earnings at $63.27 EPS. Featured ArticlesReceive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.